Repeated treatment with, but not single administration of drugs which impair dopaminergic transmission produced a consistent reduction in substance P immunoreactivity in the rat substantia nigra. This effect appears to be related to the D-2 dopamine receptor function as the blockade of this receptor subtype by selective antagonists produced effects qualitatively similar to those produced by drugs lacking selectivity for different subclasses of dopamine receptors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0014-2999(84)90664-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Population pharmacokinetics of blonanserin in Japanese adolescent and adult patients with schizophrenia.
Drug Metab Pharmacokinet
November 2024
Clinical Research, Drug Development Division, Sumitomo Pharma Co., Ltd., 33-94, Enoki-cho, Suita, Osaka, 564-0053, Japan. Electronic address:
The second-generation antipsychotic blonanserin is a highly selective, full antagonist of dopamine D and D and serotonin 5-HT receptors. It is currently prescribed for patients with schizophrenia in Japan. We aimed to develop a population pharmacokinetic model of oral blonanserin, including data from 12 to 77 years old patients, to assess the covariates that influence blonanserin pharmacokinetics and evaluate appropriate dosage regimens in adolescents versus adults.
View Article and Find Full Text PDFExploring the Pharmacological and Clinical Features of Lumateperone: A Promising Novel Antipsychotic.
Int J Mol Sci
December 2024
Section of Affective Disorders, Department of Psychiatry, Jagiellonian University Medical College, Kopernika 21a, 31-501 Kraków, Poland.
Lumateperone is a novel antipsychotic recently approved for the treatment of schizophrenia. Its unique pharmacological profile includes modulation of serotonergic, dopaminergic, and glutamatergic neurotransmission, differentiating it from other second-generation antipsychotics. This paper explores the pharmacological features and clinical potential of lumateperone across neuropsychiatric conditions.
View Article and Find Full Text PDFGenetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D receptor availability in healthy individuals.
Mol Psychiatry
December 2024
From the Clinical & Translational Neuroscience Branch, Intramural Research Program, National Institute of Mental Health, NIH, DHHS, Bethesda, MD, 20892, USA.
Dysfunction of dopamine systems has long been considered a hallmark of schizophrenia, and nearly all current first-line medication treatments block dopamine D receptors. However, approximately a quarter of patients will not adequately respond to these agents and are considered treatment-resistant. Whereas abnormally high striatal presynaptic dopamine synthesis capacity has been observed in people with schizophrenia, studies of treatment-resistant patients have not shown this pattern and have even found the opposite - i.
View Article and Find Full Text PDFRoles of metabotropic signaling of nicotine receptors in the development and maintenance of nicotine reward through regulation of dopamine D receptor expression.
J Neurochem
January 2025
College of Pharmacy, Chonnam National University, Gwangju, Republic of Korea.
The α4β2 nicotinic acetylcholine receptor (nAChR), an ionophore, has been suggested to signal through metabotropic pathways and interact with other receptor families, such as dopamine receptors. In this study, the interaction between α4β2 nAChR and dopamine receptors was investigated through in vivo and in vitro studies. Nicotine exposure in adolescent rats is known to induce a sustained increase in nicotine's rewarding effects which was assessed by conditioned place preference (CPP) assay.
View Article and Find Full Text PDFInteraction between the dopaminergic and endocannabinoid systems promotes peripheral antinociception.
Eur J Pharmacol
January 2025
Laboratory of Pain and Analgesia, Department of Pharmacology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Electronic address:
Background: Dopamine has been widely related to pain modulation, at central and peripheral levels. In this study we aimed to investigate the mechanisms involved in peripheral antinociception, evaluating the interaction between the dopaminergic and endocannabinoid systems in this event.
Methods: Male Swiss mice (30-40 g) were pre-sensitized by administration of the hyperalgesic PGE (2 μg/paw).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!